[Social vulnerability, survival, and hospital lethality by COVID-19 in patients aged 50 years and over: retrospective cohort of cases in Brazil in 2020 and 2021].
Ivan Lira Dos SantosIvan Ricardo ZimmermannMaria Rita DonalisioMariana Reis SantimariaMauro Niskier SanchezJonas Lotufo Brant de CarvalhoFlávia Silvia Arbex BorimPublished in: Cadernos de saude publica (2022)
The outcome of SARS-CoV-2 infection is not only associated with age and comorbidities but is also aggravated by social vulnerability. This study aims to analyze - according to social vulnerability - survival and hospital lethality by COVID-19 in the first 100 days from symptoms to death in individuals aged 50 years or older hospitalized in Brazil. This is a retrospective cohort from Epidemiological Week 11 of 2020 to week 33 of 2021. The Influenza Epidemiological Surveillance Information System (SIVEP-Gripe) provided clinical and epidemiological data. The Geographic Index of the Socioeconomic Context for Health and Social Studies (GeoSES) measured social vulnerability. The Kaplan-Meier curve and the adjusted proportional risk model by Cox were used for survival, with hazard ratio (HR) and 95% confidence intervals (95%CI). Among the 410,504 cases, overall lethality was of 42.2% in general and 51.4% in the most vulnerable. We found a higher lethality according to worse socioeconomic status in all categories by age group; the double is registered for 50-59 years. The adjusted Cox model showed a 32% increase in risk of death (HR = 1.32; 95%CI: 1.24-1.42). Moreover, men, older adults, black or indigenous adults, with multiple comorbidities, and subjected to invasive ventilation, have a higher risk of death after hospitalization. Intersectoral policy measures need to be targeted to alleviate the effects of the COVID-19 pandemic aggravated by social vulnerability.
Keyphrases
- healthcare
- mental health
- climate change
- public health
- coronavirus disease
- sars cov
- physical activity
- end stage renal disease
- ejection fraction
- randomized controlled trial
- drug delivery
- risk assessment
- emergency department
- clinical trial
- middle aged
- intensive care unit
- respiratory syndrome coronavirus
- adverse drug
- cross sectional
- sleep quality
- community dwelling
- health promotion
- drug induced
- patient reported outcomes
- patient reported